HCW Biologics (HCWB) Surges on Q1 2026 EPS Beat & Revenue Jump

Font: Financial Modeling Prep  • May 15, 2026

HCW Biologics Inc. (NASDAQ: HCWB) Surges After Q1 2026 EPS Beat, Licensing-Driven Revenue Jump

• HCW Biologics Inc. reported Q1 2026 earnings per share of $0.37, sharply above the analyst estimate of a $0.44 loss per share.
• The company generated $6.54 million in total revenue, compared with only $5,06 in revenue in the prior-year quarter.
• Shares of HCW Biologics surged 122.55% to $0.75 in after-hours trading following the earnings release, according to Benzinga.
• Despite the positive quarterly result, the company continues to face significant financial risks, including a low current ratio, debt obligations, Nasdaq listing concerns, and going-concern uncertainty.

HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases associated with chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The company is also advancing HCW9302, an injectable interleukin-2 fusion protein being studied in a Phase 1 clinical trial for alopecia areata.

On May 14, 2026, after the market close, HCW Biologics reported financial results for the three months ended March 31, 2026. The company posted net income attributable to common stockholders of $1.98 million, compared with a loss of $2.20 million in the prior-year quarter. Basic and diluted EPS were $0.37, compared with a loss of $1.97 per share in Q1 2025.

Revenue rose to $6.54 million from $5,06 a year earlier. However, investors should note that the increase was primarily driven by the closing of an exclusive worldwide licensing agreement with Beijing Trimmune Biotech for HCW11-006. The nonrefundable upfront license fee included $3.5 million in gross cash proceeds and a $3.5 million in-kind equity interest in Trimmune.

Following the report, HCW Biologics shares surged 122.55% to $0.75 in after-hours trading. Benzinga attributed the move to the company’s earnings beat and the sharp licensing-driven revenue turnaround.

The company also reported progress in its Phase 1 clinical study of HCW9302 for alopecia areata. HCW Biologics said two clinical sites were actively enrolling patients, no dose-limiting toxicities had been reported to date, and a full Phase 1 human data readout was expected in the fourth quarter of 2026.

Despite the positive quarter, the company’s financial position remains risky. As of March 31, 2026, HCW Biologics had $1.72 million in current assets and $19.96 million in current liabilities, implying a current ratio of approximately 0.09. A current ratio below 1 can indicate difficulty meeting short-term obligations with available current assets.

The company also had $6.58 million in short-term debt and $5.76 million in stockholders’ equity, implying a debt-to-equity ratio of approximately 1.14 using short-term debt as the debt measure. In addition, HCW Biologics disclosed that substantial doubt exists about its ability to continue as a going concern for at least 12 months without additional funding or financial support.